1. Kimball AB, Prens EP, Bechara FG, et al. Efficacy and safety of the oral Bruton’s tyrosine kinase inhibitor, remibrutinib, in patients with moderate to severe hidradenitis suppurativa in a randomized, phase 2, double-blind, placebo-controlled platform study. Late-breaking abstract. In: American Academy of Dermatology Annual Meeting, 8–12 March 2024, San Diego.
2. Kimball AB, Ackerman L, Lima H, et al. A phase 2 multicenter, randomized, double-blind placebo-controlled study to evaluate the safety and efficacy of lutikizumab in adult patients with moderate to severe hidradenitis suppurativa who have failed anti-TNF therapy. Late-breaking abstract. In: American Academy of Dermatology Annual Meeting, 8–12 March 2024, San Diego.
3. Kimball AB, Kirby B, Bechara GF, et al. Efficacy and safety of the IL-17A- and IL-17F-inhibiting Nanobody® sonelokimab in patients with moderate-to-severe hidradenitis suppurativa (HS): Week 24 results from the Phase 2 MIRA trial. Late-breaking abstract. In: American Academy of Dermatology Annual Meeting, 8–12 March 2024, San Diego, CA, USA.
4. Papp KA, et al. Efficacy and safety of ESK-001, a highly selective oral TYK2 inhibitor, in a phase 2 study in adults with moderate-to-severe plaque psoriasis (STRIDE). Late-breaking abstract. In: American Academy of Dermatology Annual Meeting, 8–12 March 2024, San Diego.
5. Bissonnette R, Pinter A, Ferris LK, et al. An oral interleukin-23-receptor antagonist peptide for plaque psoriasis. N Engl J Med. 2024;390(6):510–21. https://doi.org/10.1056/NEJMoa2308713.